相关实验视频

Updated: Jul 11, 2025

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

一种组合治疗方法来增强FLT3-ITDAML治疗方法

Jun Long¹, Xinjie Chen², Yan Shen³

¹Department of Hematology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China; Department of Hematology, Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Cell reports. Medicine

|November 11, 2023

概括

通过降低p53蛋白的稳定性,FLT3抑制剂可以导致急性髓性白血病 (AML) 的耐药性. 将蛋白酶体抑制剂与FLT3抑制剂结合起来,可以恢复p53并改善AML治疗结果.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

类似FMS的氨酸激酶-3 (FLT3-ITDs) 的内部并列重复在急性髓性白血病 (AML) 中很常见,与预后不佳相关.
目前FLT3抑制剂的疗效有限,因此需要针对FLT3-ITDAML制定新的治疗策略.

研究的目的:

研究FLT3抑制剂治疗的FLT3-ITDAML中药物耐药性的机制.
评估将蛋白酶体抑制剂与FLT3抑制剂结合用于FLT3-ITDAML的治疗潜力.

主要方法:

使用了FLT3-ITDAML的细胞系,小鼠模型和患者样本.
评估FLT3抑制剂对p53蛋白稳定性的影响.
研究了将蛋白酶体抑制剂与FLT3抑制剂结合的疗效.

主要成果:

发现FLT3抑制剂降低了抗癌蛋白p53的稳定性,导致药物耐药性.
使用蛋白酶抑制剂阻断p53降解恢复了细胞内p53水平.
组合疗法在临床前模型和患者衍生样本中显示出增强的治疗效果.

结论:

降低p53稳定性是AML中对FLT3抑制剂耐药性的机制.
将蛋白酶体抑制剂与FLT3抑制剂结合起来,是FLT3-ITDAML的一种有前途的治疗策略.
这种方法需要进一步的临床研究,以改善患者的治疗结果.

关键词:

这是一种FLT3抑制剂.在FLT3-ITDD中使用.我的世界 MYC USP10 10美元的价格急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.在 p53 里,p53 是一个 p53 的类型.蛋白酶体抑制剂是一种蛋白酶体抑制剂.无处不在的化

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.